Acknowledgements We would like to thank the subjects who participated in the trial. Funding This study was supported by MEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany. Technical, editorial, and medical writing assistance was provided under the direction of the authors by Strategix, an affiliate of The Lynx Group, LLC. Funding for this support was provided by Mylan Inc.Peer reviewedPublisher PD
International audienceAllergic rhinitis (AR) is prevalent, and many patients present with moderate-t...
Allergic rhinitis (AR) is the most widespread type of non-infectious rhinitis. In 2001, the Allergic...
Epidemiological studies on respiratory allergies have shown that allergic rhinitis (AR) and bronchia...
Background: MP-AzeFlu (Dymista (R); spray of azelastine/fluticasone propionate) is the most effectiv...
Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies C...
Funding for this research was provided by Mylan Inc. Acknowledgements We thank Dr Ruth B Murray (Med...
Background: Some aspects of allergic march still need to be addressed. To prevent the onset of the m...
OBJECTIVE: The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu ...
Background: This article summarizes a EUFOREA symposium, presented during the European Rhinology Res...
Introduction: Allergic rhinitis (AR) is a global health problem and one of the most common condition...
The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provide a stepwise treatment to rhi...
The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized...
OBJECTIVE: To determine the characteristics of asthma (A) and allergic rhinitis (AR) among asthma pa...
Funding Information: JH was financed by a grant from the Swedish Society of Medicine. The RHINE stud...
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general ...
International audienceAllergic rhinitis (AR) is prevalent, and many patients present with moderate-t...
Allergic rhinitis (AR) is the most widespread type of non-infectious rhinitis. In 2001, the Allergic...
Epidemiological studies on respiratory allergies have shown that allergic rhinitis (AR) and bronchia...
Background: MP-AzeFlu (Dymista (R); spray of azelastine/fluticasone propionate) is the most effectiv...
Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies C...
Funding for this research was provided by Mylan Inc. Acknowledgements We thank Dr Ruth B Murray (Med...
Background: Some aspects of allergic march still need to be addressed. To prevent the onset of the m...
OBJECTIVE: The aims of this study were (1) to characterise the type of patient prescribed MP-AzeFlu ...
Background: This article summarizes a EUFOREA symposium, presented during the European Rhinology Res...
Introduction: Allergic rhinitis (AR) is a global health problem and one of the most common condition...
The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines provide a stepwise treatment to rhi...
The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized...
OBJECTIVE: To determine the characteristics of asthma (A) and allergic rhinitis (AR) among asthma pa...
Funding Information: JH was financed by a grant from the Swedish Society of Medicine. The RHINE stud...
Background: Allergic Rhinitis (AR) is a high-prevalence disease. In Europe about 25% of the general ...
International audienceAllergic rhinitis (AR) is prevalent, and many patients present with moderate-t...
Allergic rhinitis (AR) is the most widespread type of non-infectious rhinitis. In 2001, the Allergic...
Epidemiological studies on respiratory allergies have shown that allergic rhinitis (AR) and bronchia...